COPD
Conditions
Interventions
We conducted a randomized, crossover study comparing the adherence to and efficacy of LABA between the transdermal tulobuterol patch (TP, 2 mg once a day) and inhaled salmeterol (50 &
g, twice a day) in elderly COPD patients.
We conducted a randomized, crossover study comparing the adherence to and efficacy of LABA between the transdermal tulobuterol patch (TP, 2 mg once a day) an
g, twice a day) in elderly COPD patients.
Sponsors
The Tokyo Metropolitan Geriatric Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients had clinical features consistent with the presence of moderate-to-severe COPD including the spirometric criteria of post-bronchodilator FEV1/FVC ratio of less than 0.7 and FEV1 between 30% and 80% of the predicted values for height and age, and their condition remained stable during the past month.
Exclusion criteria
Exclusion criteria: The exclusion criteria included age younger than 65 years, dementia and any previously use of inhaled medications such as 2-agonists, anti-cholinergics or corticosteroids, patched 2-agonist, or systemic corticosteroids. Patients with dermatological disorders, severe heart diseases, uncontrolled hypertension or other diseases for which patch preparations or treatments with 2-agonists was considered inappropriate were also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcomes were adherence to the medication and change in a 6-minute walk distance (6MWD). | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes were spirometric values and quality of life (QOL) measured by the St.George's Respiratory Questionnaire. | — |
Countries
Japan
Contacts
Public ContactHideki Takahashi
The Tokyo Metropolitan Geriatric Hospital Division of Respiratory Medicine
Outcome results
None listed